Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib

Atopic dermatitis (AD) is a clinically heterogenous, inflammatory skin condition with a high impact on patients’ daily activities that remains difficult to treat. The knowledge acquired over the last decade on AD pathophysiology and disease burden led to the development of new targeted therapeutic...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Miguel Nogueira, Tiago Torres
Formato: article
Lenguaje:EN
Publicado: Mattioli1885 2021
Materias:
Acceso en línea:https://doaj.org/article/f2263195ebd44087a6390424e7c41784
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!